Prostate cancer stem-like cells proliferate slowly and resist etoposide-induced cytotoxicity via enhancing DNA damage response

Experimental Cell Research

Volumn 328, Issue 1, 2014, Pages 132-142

  Yan, Judy ^a,b,c   Tang, Damu ^a,b,c  

^a ST JOSEPH S HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c St Joseph's Healthcare Hamilton   (Canada)

Author keywords

Cell proliferation; Cell signaling; DNA damage response; Prostate cancer stem cell; Tumorigenesis

Indexed keywords

DOCETAXEL; ETOPOSIDE; GROWTH FACTOR; PROTEIN KINASE B; REAGENT; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; MALE; MOUSE; NONHUMAN; XENOGRAFT; ANIMAL; APOPTOSIS; CFU COUNTING; DRUG EFFECTS; ENZYME IMMUNOASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HUMAN; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS; SCID MOUSE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; DNA DAMAGE; ETOPOSIDE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84908011946     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.08.016     Document Type: Article

References (58)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: Cancer J. Clin. 2011, 61:69-90.
2. Moon C., Park J.C., Chae Y.K., Yun J.H., Kim S. Current status of experimental therapeutics for prostate cancer. Cancer Lett. 2008, 266:116-134.
3. el-Kamar F.G., Grossbard M.L., Kozuch P.S. Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care. Oncologist 2003, 8:18-34.
4. Chen Y., Sawyers C.L., Scher H.I. Targeting the androgen receptor pathway in prostate cancer. Curr. Opin. Pharmacol. 2008, 8:440-448.
5. Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 2000, 42:150-160.
6. Fiorentini C., Bodei S., Bedussi F., Fragni M., Bonini S.A., Simeone C., Zani D., Berruti A., Missale C., Memo M., Spano P., Sigala S. GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity. Exp. Cell Res. 2014, 323:100-111.
7. Bjerklund Johansen T.E., Witzsch U., Greene D. Salvage treatment in prostate cancer: a clinical approach. Expert Rev. Anticancer Ther. 2013, 13:613-623.
8. Damber J.E., Aus G. Prostate cancer. Lancet 2008, 371:1710-1721.
9. Baccelli I., Trumpp A. The evolving concept of cancer and metastasis stem cells. J. Cell Biol. 2012, 198:281-293.
10. Chauchereau A., Al Nakouzi N., Gaudin C., Le Moulec S., Compagno D., Auger N., Benard J., Opolon P., Rozet F., Validire P., Fromont G., Fizazi K. Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer. Exp. Cell Res. 2011, 317:262-275.
11. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
12. Hellsten R., Johansson M., Dahlman A., Sterner O., Bjartell A. Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells. PLoS One 2011, 6:e22118.
13. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8:755-768.
14. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
15. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J., Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
16. Shi M.F., Jiao J., Lu W.G., Ye F., Ma D., Dong Q.G., Xie X. Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line. Cell. Mol. Life Sci. 2010, 67:3915-3925.
17. Wright M.H., Calcagno A.M., Salcido C.D., Carlson M.D., Ambudkar S.V., Varticovski L. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 2008, 10:R10.
18. Qin J., Liu X., Laffin B., Chen X., Choy G., Jeter C.R., Calhoun-Davis T., Li H., Palapattu G.S., Pang S., Lin K., Huang J., Ivanov I., Li W., Suraneni M.V., Tang D.G. The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell 2012, 10:556-569.
19. Colombel M., Eaton C.L., Hamdy F., Ricci E., van der Pluijm G., Cecchini M., Mege-Lechevallier F., Clezardin P., Thalmann G. Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases. Prostate 2012, 72:713-720.
20. Wang Z.A., Mitrofanova A., Bergren S.K., Abate-Shen C., Cardiff R.D., Califano A., Shen M.M. Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat. Cell Biol. 2013, 15:274-283.
21. Baba T., Convery P.A., Matsumura N., Whitaker R.S., Kondoh E., Perry T., Huang Z., Bentley R.C., Mori S., Fujii S., Marks J.R., Berchuck A., Murphy S.K. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009, 28:209-218.
22. Yu X., Lin Y., Yan X., Tian Q., Li L., Lin E.H. CD133, stem cells, and cancer stem cells: myth or reality?. Curr. Colorectal Cancer Rep. 2011, 7:253-259.
23. Bhattacharya S., Ray R.M., Johnson L.R. Role of polyamines in p53-dependent apoptosis of intestinal epithelial cells. Cell Signal. 2009, 21:509-522.
24. Lord C.J., Ashworth A. The DNA damage response and cancer therapy. Nature 2012, 481:287-294.
25. Pabla N., Ma Z., McIlhatton M.A., Fishel R., Dong Z. hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis. J. Biol. Chem. 2011, 286:10411-10418.
26. Rybak A.P., He L., Kapoor A., Cutz J.C., Tang D. Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells. Biochim. Biophys. Acta 2011, 1813:683-694.
27. Wei F., Xie Y., Tao L., Tang D. Both ERK1 and ERK2 kinases promote G2/M arrest in etoposide-treated MCF7 cells by facilitating ATM activation. Cell Signal. 2010, 22:1783-1789.
28. Dalerba P., Cho R.W., Clarke M.F. Cancer stem cells: models and concepts. Annu. Rev. Med. 2007, 58:267-284.
29. Dubrovska A., Kim S., Salamone R.J., Walker J.R., Maira S.M., Garcia-Echeverria C., Schultz P.G., Reddy V.A. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc. Natl. Acad. Sci. USA 2009, 106:268-273.
30. Ponti D., Costa A., Zaffaroni N., Pratesi G., Petrangolini G., Coradini D., Pilotti S., Pierotti M.A., Daidone M.G. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005, 65:5506-5511.
31. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
32. Boonstra J. Progression through the G1-phase of the on-going cell cycle. J. Cell. Biochem. 2003, 90:244-252.
33. Hulleman E., Boonstra J. Regulation of G1 phase progression by growth factors and the extracellular matrix. Cell. Mol. Life Sci. 2001, 58:80-93.
34. Jones S.M., Kazlauskas A. Growth factor-dependent signaling and cell cycle progression. FEBS Lett. 2001, 490:110-116.
35. Cheung T.H., Rando T.A. Molecular regulation of stem cell quiescence. Nat. Rev. Mol. Cell Biol. 2013, 14:329-340.
36. Lee J., Son M.J., Woolard K., Donin N.M., Li A., Cheng C.H., Kotliarova S., Kotliarov Y., Walling J., Ahn S., Kim M., Totonchy M., Cusack T., Ene C., Ma H., Su Q., Zenklusen J.C., Zhang W., Maric D., Fine H.A. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008, 13:69-80.
37. Brader S., Eccles S.A. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 2004, 90:2-8.
38. Grille S.J., Bellacosa A., Upson J., Klein-Szanto A.J., van Roy F., Lee-Kwon W., Donowitz M., Tsichlis P.N., Larue L. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 2003, 63:2172-2178.
39. Nalla A.K., Estes N., Patel J., Rao J.S. N-cadherin mediates angiogenesis by regulating monocyte chemoattractant protein-1 expression via PI3K/Akt signaling in prostate cancer cells. Exp. Cell Res. 2011, 317:2512-2521.
40. Toker A., Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. Cancer Res. 2006, 66:3963-3966.
41. Gao N., Zhang Z., Jiang B.H., Shi X. Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem. Biophys. Res. Commun. 2003, 310:1124-1132.
42. Liang J., Slingerland J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003, 2:339-345.
43. McDonald G.T., Sullivan R., Pare G.C., Graham C.H. Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression. Exp. Cell Res. 2010, 316:3197-3206.
44. Kamradt J.M., Pienta K.J. Etoposide in prostate cancer. Expert Opin. Pharmacother. 2000, 1:271-275.
45. Hadaschik B.A., Gleave M.E. Therapeutic options for hormone-refractory prostate cancer in 2007. Urol. Oncol. 2007, 25:413-419.
46. Zhou B.B., Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature 2000, 408:433-439.
47. Abraham R.T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 2001, 15:2177-2196.
48. Wei F., Xie Y., He L., Tao L., Tang D. ERK1 and ERK2 kinases activate hydroxyurea-induced S-phase checkpoint in MCF7 cells by mediating ATR activation. Cell Signal. 2011, 23:259-268.
49. Mok M.T., Henderson B.R. A comparison of BRCA1 nuclear localization with 14 DNA damage response proteins and domains: identification of specific differences between BRCA1 and 53BP1 at DNA damage-induced foci. Cell Signal. 2009, 22:47-56.
50. Stewart G.S., Wang B., Bignell C.R., Taylor A.M., Elledge S.J. MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature 2003, 421:961-966.
51. Redon C., Pilch D., Rogakou E., Sedelnikova O., Newrock K., Bonner W. Histone H2A variants H2AX and H2AZ. Curr. Opin. Genet. Dev. 2002, 12:162-169.
52. Patrawala L., Calhoun T., Schneider-Broussard R., Li H., Bhatia B., Tang S., Reilly J.G., Chandra D., Zhou J., Claypool K., Coghlan L., Tang D.G. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006, 25:1696-1708.
53. Crown J., O'Shaughnessy J., Gullo G. Emerging targeted therapies in triple-negative breast cancer. Ann. Oncol. 2012, 23(Suppl 6):Svi56-Svi65.
54. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., Zhu J., Johnson D.H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346:92-98.
55. Gasser S., Raulet D. The DNA damage response, immunity and cancer. Semin. Cancer Biol. 2006, 16:344-347.
56. Harper J.W., Elledge S.J. The DNA damage response: ten years after. Mol. Cell 2007, 28:739-745.
57. Sancar A., Lindsey-Boltz L.A., Unsal-Kacmaz K., Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 2004, 73:39-85.
58. Maugeri-Sacca M., Bartucci M., De Maria R. DNA damage repair pathways in cancer stem cells. Mol. Cancer Ther. 2012, 11:1627-1636.